FDA Approves VIGABATRIN — Cipla USA, Inc.

# FDA Approves Vigabatrin Generic from Cipla USA Cipla USA, Inc. received FDA approval for its generic vigabatrin oral formulation, expanding the competitive landscape for this seizure medication and potentially driving down treatment costs for patients with infantile spasms and refractory epilepsy. The approval of the ANDA application marks another entry into the vigabatrin market, likely to intensify price competition and increase accessibility to this critical neurological therapy.